TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1555312

Group type: EXPERIMENTAL
Intervention: Intranasal splints inserted for 7 days
Number of subjects: 100

Group type: COMPARATOR
Intervention: No splints (control group)
Number of subjects: 100
Study: 2861791

Group type: EXPERIMENTAL
Intervention: Intranasal luteinising hormone releasing hormone (1200 micrograms/day for 28 days)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 40
Study: 30396037

Group type: EXPERIMENTAL
Intervention: OHES + ART (n=39)
Number of subjects: 78

Group type: COMPARATOR
Intervention: ART (n=39)
Number of subjects: 78
Study: 30249583

Group type: EXPERIMENTAL
Intervention: Blended CBT (Web-based program + 12 face-to-face sessions of 45 minutes each)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Blended CBT (follow-up at week 24)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Blended CBT (posttreatment at week 12)
Number of subjects: 40
Study: 26807502

Group type: EXPERIMENTAL
Intervention: 1000 mg omega 3-PUFA supplementation
Number of subjects: 205
Study: 24479817

Group type: EXPERIMENTAL
Intervention: Gain-framed messages
Number of subjects: 77

Group type: COMPARATOR
Intervention: Loss-framed messages
Number of subjects: 77
Study: 21448637

Group type: EXPERIMENTAL
Intervention: LED curing unit with two-component self-etching primers
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: QTH curing unit with two-component self-etching primers
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Two-component self-etching primers
Number of subjects: 500

Group type: COMPARATOR
Intervention: Acid-etching method
Number of subjects: 500
Study: 19092677

Group type: EXPERIMENTAL
Intervention: Unidirectional stimulation with high intensity
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Unidirectional stimulation with large anode to small cathode
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Unidirectional stimulation with small anode to large cathode
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: More intense stimulation
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Smaller electrode size
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Varying intensity and electrode geometry
Number of subjects: 19
Study: 17687719

Group type: EXPERIMENTAL
Intervention: Combination of fluticasone propionate and salmeterol, 500/100 microg daily (group 1; n = 52)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Beclomethasone, 1000 microg daily, and salbutamol inhaler, 800 microg daily (group 2; n = 53)
Number of subjects: 105
Study: 15633616

Group type: EXPERIMENTAL
Intervention: Amiodarone (200 to 400 mg/d)
Number of subjects: 0

Group type: COMPARATOR
Intervention: AV node radiofrequency ablation (RFA) and permanent His-bundle pacing
Number of subjects: 0
Study: 11800586

Group type: EXPERIMENTAL
Intervention: DPPD
Number of subjects: 51

Group type: COMPARATOR
Intervention: PPD
Number of subjects: 51
Study: 9732379

Group type: EXPERIMENTAL
Intervention: Pentazocine (30 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Pentazocine (7.5 to 30 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Morphine (10 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Pentazocine
Number of subjects: 16
Study: 8064214

Group type: EXPERIMENTAL
Intervention: Smoked marijuana
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo cigarettes
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Progressive-interval schedule performance
Number of subjects: 8
Study: 3353895

Group type: EXPERIMENTAL
Intervention: House dust mite avoidance measures (including liquid nitrogen application to mattresses and carpets)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: House dust mite avoidance measures
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 21
Study: 31003676

Group type: EXPERIMENTAL
Intervention: Auricular acupressure using vaccaria seeds
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo auricular acupressure using vaccaria seeds
Number of subjects: 58
Study: 28592234

Group type: EXPERIMENTAL
Intervention: Branded Marevan® (Uniao Quimica/Farmoquimica)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Generic warfarin (Uniao Quimica Farmaceutica Nacional)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Generic warfarin (Laboratorio Teuto Brasileiro)
Number of subjects: 0
Study: 25740387

Group type: EXPERIMENTAL
Intervention: Carboplatin plus paclitaxel combined with cetuximab (arm A)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Carboplatin plus paclitaxel combined with cixutumumab (arm B)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Carboplatin plus paclitaxel combined with both cetuximab and cixutumumab (arm C)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (not explicitly defined, but implied as no treatment or standard care)
Number of subjects: 140
Study: 23497452

Group type: EXPERIMENTAL
Intervention: Fulvestrant 500 mg plus Anastrozole 1 mg/day for 14 to 21 days (F + A)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Fulvestrant 500 mg plus Anastrozole placebo (F)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Anastrozole alone (A)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: All treatments (F, F + A, A)
Number of subjects: 121
Study: 22020892

Group type: EXPERIMENTAL
Intervention: Voice rest
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Resonant voice exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spontaneous speech
Number of subjects: 0
Study: 19301041

Group type: COMPARATOR
Intervention: rhBMP-2
Number of subjects: 0
Study: 16785262

Group type: EXPERIMENTAL
Intervention: Aromatase inhibitor (letrozole 2.5 mg daily from cycle days 2 to 8)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Androgen priming with aromatase inhibitor and hCG (1250 IU s.c. on cycle day 2)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (no other pretreatment)
Number of subjects: 45
Study: 15385877

Group type: EXPERIMENTAL
Intervention: AGF platelet gel
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control (no AGF)
Number of subjects: 84
Study: 15332782

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation with antirabies vaccine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group receiving only the antirabies vaccine
Number of subjects: 40
Study: 9241094

Group type: EXPERIMENTAL
Intervention: Spironolactone: beta-cyclodextrin complex (SP-COMP)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Aldactone tablets (ALD)
Number of subjects: 13
Study: 8302149

Group type: EXPERIMENTAL
Intervention: Intravenous midazolam 0.05 mg/kg, meperidine 1 mg/kg, and buscopan 20 mg (Group IV‐MMB)
Number of subjects: 299

Group type: COMPARATOR
Intervention: Intramuscular meperidine 50 mg and buscopan 20 mg (Group IM‐MB)
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 299
Study: 3127114

Group type: EXPERIMENTAL
Intervention: Oral administration of combination oral contraceptive tablet (250 micrograms LNG and 50 micrograms EE2)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Vaginal administration of combination oral contraceptive tablet (250 micrograms LNG and 50 micrograms EE2)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Intravenous administration of combination oral contraceptive tablet (250 micrograms LNG and 50 micrograms EE2)
Number of subjects: 5
Study: 31665873

Group type: EXPERIMENTAL
Intervention: Caffeine (CAF: 6 mg/kg body mass)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Caffeine (CAF)
Number of subjects: 9
Study: 29091512

Group type: EXPERIMENTAL
Intervention: Drop Vertical Jump (DVJ)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Step-Down Test (SDT)
Number of subjects: 60
Study: 29157276

Group type: EXPERIMENTAL
Intervention: Non-Surgical Periodontal Therapy (NSPT)
Number of subjects: 66

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 66
Study: 25721919

Group type: EXPERIMENTAL
Intervention: Fibrin sealant
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional suturing
Number of subjects: 30
Study: 23219296

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 15056

Group type: COMPARATOR
Intervention: Atorvastatin 10 mg and simvastatin 20 to 40 mg
Number of subjects: 15056

Group type: COMPARATOR
Intervention: Lower-dose statin therapy (Atorvastatin 10 mg and simvastatin 20 to 40 mg)
Number of subjects: 15056
Study: 22286630

Group type: EXPERIMENTAL
Intervention: Pterygium excision with complete suture of conjunctiva (PESC)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Pterygium excision with conjunctival auto‐graft transplantation with graft from the inferior temporal bulbar conjunctiva (ITBC)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Pterygium excision with conjunctival auto‐graft transplantation with graft from the superior temporal bulbar conjunctiva (STBC)
Number of subjects: 120
Study: 19359622

Group type: EXPERIMENTAL
Intervention: EMS intervention with strategic placement of stroke education media
Number of subjects: 5

Group type: COMPARATOR
Intervention: Control counties with no EMS intervention
Number of subjects: 5
Study: 15976922

Group type: EXPERIMENTAL
Intervention: Attention Network Test - Executive Attention
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Attention Network Test - Effortful Control
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Attention Network Test - Negative Affectivity
Number of subjects: 41

Group type: COMPARATOR
Intervention: Attention Network Test - Alerting and Orienting
Number of subjects: 41
Study: 14690100

Group type: EXPERIMENTAL
Intervention: Sub-Tenon's bupivacaine (4-5 mL of bupivacaine 0.75%)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 43
Study: 11109391

Group type: EXPERIMENTAL
Intervention: Observational units
Number of subjects: 4

Group type: COMPARATOR
Intervention: Ordinary hospital units
Number of subjects: 4
Study: 8603458

Group type: EXPERIMENTAL
Intervention: Early prophylaxis group (rhG‐CSF initiated on day 2)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Late prophylaxis group (rhG‐CSF initiated on day 8)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Therapeutic group (rhG‐CSF initiated after onset of neutropenia)
Number of subjects: 33

Group type: COMPARATOR
Intervention: No-support group (MVP therapy without rhG‐CSF)
Number of subjects: 33
Study: 16967580

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (5 mg/kg body weight over 30 min)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 0
Study: 3840565

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 29587863

Group type: EXPERIMENTAL
Intervention: Shenzhuo Formula (SZF)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Irbesartan
Number of subjects: 120
Study: 27686945

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy plus concurrent chemoradiotherapy (3 cycles of intravenous docetaxel 60 mg/m2 on day 1, intravenous cisplatin 60 mg/m2 on day 1, continuous intravenous fluorouracil 600 mg/m2 per day from day 1 to day 5 every 3 weeks)
Number of subjects: 480

Group type: COMPARATOR
Intervention: Concurrent chemoradiotherapy alone (3 cycles of 100 mg/m2 cisplatin every 3 weeks with intensity-modulated radiotherapy)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy plus concurrent chemoradiotherapy
Number of subjects: 480

Group type: COMPARATOR
Intervention: Concurrent chemoradiotherapy alone
Number of subjects: 480
Study: 25068290

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 18
Study: 23063367

Group type: EXPERIMENTAL
Intervention: Sulfonylurea
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 0
Study: 20205486

Group type: EXPERIMENTAL
Intervention: Tolvaptan 15-60 mg once daily for up to 30 days (n = 95 in SALT-1, n = 118 in SALT-2)
Number of subjects: 536

Group type: EXPERIMENTAL
Intervention: Tolvaptan in a subgroup of 323 patients with hyponatraemia (serum sodium <134 mmol/L) in the EVEREST trials
Number of subjects: 536

Group type: COMPARATOR
Intervention: Placebo (n = 89 in SALT-1, n = 114 in SALT-2)
Number of subjects: 536
Study: 18204388

Group type: EXPERIMENTAL
Intervention: Epidural corticosteroids
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Open surgical techniques
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Cervical foramenal or epidural injections
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Open surgical procedures on the cervical spine
Number of subjects: 31

Group type: COMPARATOR
Intervention: Nonoperative measures
Number of subjects: 31
Study: 16126056

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 12114414

Group type: EXPERIMENTAL
Intervention: Pivaloyloxymethyl butyrate (AN‐9) administered as a 6‐h i.v. infusion daily for 5 days every 3 weeks at dosages ranging from 0.047 to 3.3 g/m2/day.
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Pivaloyloxymethyl butyrate (AN‐9) at maximum deliverable dose of 3.3 g/m2/day.
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Pivaloyloxymethyl butyrate (AN‐9) treatment.
Number of subjects: 28
Study: 12148423

Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy (LA group)
Number of subjects: 148
Study: 9503298

Group type: EXPERIMENTAL
Intervention: PSSWWG liner worn over an inner latex glove
Number of subjects: 50

Group type: COMPARATOR
Intervention: Double latex gloves
Number of subjects: 50
Study: 8061266

Group type: EXPERIMENTAL
Intervention: Ketanserin (5 mg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 50
Study: 3293527

Group type: EXPERIMENTAL
Intervention: Aerosolized ribavirin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31983585

Group type: EXPERIMENTAL
Intervention: Human rotavirus vaccine (HRV), Rotarix, administered over a three-year period.
Number of subjects: 10917

Group type: COMPARATOR
Intervention: Non-HRV villages (control group).
Number of subjects: 10917

Group type: EXPERIMENTAL
Intervention: HRV villages.
Number of subjects: 10917

Group type: EXPERIMENTAL
Intervention: HRV villages with literate mothers.
Number of subjects: 10917

Group type: COMPARATOR
Intervention: Non-HRV villages.
Number of subjects: 10917

Group type: EXPERIMENTAL
Intervention: HRV villages with higher phone users.
Number of subjects: 10917
Study: 30985861

Group type: EXPERIMENTAL
Intervention: Indirect patient care
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Direct patient care
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Education
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Multitasking with indirect patient care activities
Number of subjects: 80
Study: 29093068

Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA 1,000 U
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA 1,500 U
Number of subjects: 381

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Open-label cycles (1,000 U, 1,500 U)
Number of subjects: 381
Study: 25736977

Group type: EXPERIMENTAL
Intervention: Computer-assisted tobacco intervention tool
Number of subjects: 1

Group type: COMPARATOR
Intervention: Control (non-intervention clinic)
Number of subjects: 1
Study: 22730906

Group type: COMPARATOR
Intervention: 1,000 mg paracetamol
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: 400 mg etodolac
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: 800 mg etodolac
Number of subjects: 229
Study: 21631623

Group type: EXPERIMENTAL
Intervention: Longitudinal models (mixed-effects and generalized estimating equations)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Generalized estimating equations (GEE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Longitudinal models
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Previous day's smoking status and recent smoking history
Number of subjects: 0
Study: 18440325

Group type: COMPARATOR
Intervention: Renin angiotensin system blockade (RAS blockade)
Number of subjects: 45758
Study: 18473977

Group type: EXPERIMENTAL
Intervention: Participation in clinical trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pediatric trial design
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ethical issues in trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Legal situation in clinical trials
Number of subjects: 0
Study: 12674390

Group type: EXPERIMENTAL
Intervention: Group visits
Number of subjects: 120

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 120
Study: 11103193

Group type: EXPERIMENTAL
Intervention: PCEA ropivacaine 0.1%, bolus 5 mg, lock-out 15 min, 3 mg h-1 background infusion (group R)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: PCEA 0.1% ropivacaine/fentanyl 2 micrograms ml-1 at identical settings (group RF)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: PCEA 0.1% ropivacaine/fentanyl (group RF)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: PCEA 0.1% ropivacaine (group R)
Number of subjects: 47
Study: 8814420

Group type: EXPERIMENTAL
Intervention: Quantitative REM sleep EEG
Number of subjects: 9

Group type: COMPARATOR
Intervention: SPECT measures
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Degrees of interhemispheric asymmetry
Number of subjects: 9
Study: 14621842

Group type: EXPERIMENTAL
Intervention: RS-61443 (morpholinoethyl ester of mycophenolic acid)
Number of subjects: 0
Study: 30939410

Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL) 800 mg qAM
Number of subjects: 23

Group type: COMPARATOR
Intervention: Carbamazepine (CBZ) 400 mg BID
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Carbamazepine (CBZ)
Number of subjects: 23
Study: 28597333

Group type: EXPERIMENTAL
Intervention: Pastor support and engagement in promoting the intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pastor engagement in promoting the program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pastor attendance at workshops
Number of subjects: 0
Study: 27136316

Group type: EXPERIMENTAL
Intervention: Postural hand tremor measured by quartile (dot method)
Number of subjects: 715

Group type: EXPERIMENTAL
Intervention: Postural hand tremor measured by quartile (circular method)
Number of subjects: 715

Group type: COMPARATOR
Intervention: Postural hand tremor
Number of subjects: 715
Study: 24766756

Group type: EXPERIMENTAL
Intervention: Behavioral intervention combined with acamprosate and/or naltrexone
Number of subjects: 1156
Study: 22476809

Group type: EXPERIMENTAL
Intervention: Cisplatin + 5‐fluorouracil + radiotherapy (PF group)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Cisplatin + docetaxel + radiotherapy (DP group)
Number of subjects: 90
Study: 20510947

Group type: EXPERIMENTAL
Intervention: Music therapy (listening to music during the procedure)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No music therapy (control group)
Number of subjects: 100
Study: 17699546

Group type: COMPARATOR
Intervention: Advice and exercise
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Advice and exercise plus true acupuncture
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Advice and exercise plus non‐penetrating acupuncture
Number of subjects: 352
Study: 16198805

Group type: EXPERIMENTAL
Intervention: Miconazole powder 2% biweekly
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 12030956

Group type: EXPERIMENTAL
Intervention: Intravenous H2-receptor antagonists
Number of subjects: 0
Study: 9917121

Group type: EXPERIMENTAL
Intervention: Aplisol
Number of subjects: 1555

Group type: EXPERIMENTAL
Intervention: Tubersol
Number of subjects: 1555

Group type: EXPERIMENTAL
Intervention: PPD-S1
Number of subjects: 1555

Group type: COMPARATOR
Intervention: PPD-S2
Number of subjects: 1555
Study: 8538091

Group type: EXPERIMENTAL
Intervention: 450 micrograms/day of BDP
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 900 micrograms/day of BDP
Number of subjects: 39

Group type: COMPARATOR
Intervention: Bronchodilators only (Control)
Number of subjects: 39
Study: 2188335

Group type: EXPERIMENTAL
Intervention: AGD (aluminium‐adsorbed allergoid) injections
Number of subjects: 36

Group type: COMPARATOR
Intervention: TA (tyrosine‐adsorbed allergoid) injections
Number of subjects: 36
Study: 6268298

Group type: EXPERIMENTAL
Intervention: Cefotaxime 500 mg intramuscularly every eight hours
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cefazolin 1,000 mg intramuscularly every eight hours
Number of subjects: 0
Study: 31500986

Group type: EXPERIMENTAL
Intervention: Reverse shoulder arthroplasty (RSA)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Nonoperative treatment
Number of subjects: 59
Study: 28641416

Group type: EXPERIMENTAL
Intervention: Selenocyanate (SeCN‐) as a vibrational probe in ultrafast IR experiments
Number of subjects: 0
Study: 28638206

Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS) on the left prefrontal dorsolateral cortex (DLPFC)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 37
Study: 24557349

Group type: EXPERIMENTAL
Intervention: Serum EPA
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: RBCM EPA
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: RBCM EPA+DHA
Number of subjects: 290

Group type: COMPARATOR
Intervention: Dietary oily fish and seafood intake
Number of subjects: 290
Study: 22638798

Group type: EXPERIMENTAL
Intervention: Bevacizumab (10 mg/kg every 2 weeks), Everolimus (5 mg three times weekly), Panitumumab (4.8 mg/kg)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Everolimus (10 mg daily)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Everolimus (5 mg daily)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Common adverse events
Number of subjects: 32
Study: 19400894

Group type: EXPERIMENTAL
Intervention: Double-blind, placebo-controlled food challenge (DBPCFC)
Number of subjects: 2739

Group type: COMPARATOR
Intervention: Parental-reported IgE-mediated food allergy
Number of subjects: 2739

Group type: COMPARATOR
Intervention: Sensitization to food allergens
Number of subjects: 2739

Group type: COMPARATOR
Intervention: Odds ratio comparison between reported and confirmed IgE-mediated food allergy
Number of subjects: 2739
Study: 17938126

Group type: EXPERIMENTAL
Intervention: TAXUS MR stent
Number of subjects: 446